CBD drug Epidiolex received approval from the U.S. Food and Drug Administration to treat seizures associated with a third medical condition, expanding the range of indications for the cannabis-derived medication. Reports Hemp Industry Daily

The orally administered drug from Britain’s GW Pharmaceuticals previously was approved by the FDA to treat seizures associated with two forms of severe epilepsy, Lennox-Gastaut syndrome and Dravet syndrome.

The new FDA approval, granted July 31 to GW’s U.S. subsidiary, Greenwich Biosciences, means the drug can now be used in the United States to treat seizures associated with tuberous sclerosis complex, a genetic disease believed to affect one in 6,000 people.

Full story at. https://hempindustrydaily.com/fda-approves-gw-pharmaceuticals-cbd-drug-for-new-indication/?utm_medium=email&utm_source=newsletter&utm_campaign=HEMP_20200804_Daily&elqTrackId=BBD7264BE82DA0B9617E5F52303FFDD0&elq=ecbaa76fdaa0404db94caa1290c5173b&elqaid=3828&elqat=1&elqCampaignId=2734